Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 7,040 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Terminated Phase 3 Interventional Results available

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

NCT00272987
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, paclitaxel, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
14
States / cities
Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Optimizing Functional Recovery of Breast Cancer Survivors

NCT03915548
View directory record Official record
Conditions
Breast Cancer Female
Interventions
The Behavioral Activation/ Problem Solving Intervention, Attention Control Condition
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Breast MRI Spectroscopy

NCT00577915
View directory record Official record
Conditions
Suspicion of, or Known Breast Cancer
Interventions
Radiology/MRI scan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional

MRI to Detect Breast Tumors in Women

NCT00003302
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, mammography
Procedure · Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema

NCT04465253
View directory record Official record
Conditions
Breast Carcinoma, Lymphedema
Interventions
Best Practice, Motivational Interviewing, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 3, 2026, 10:13 AM EDT
Completed No phase listed Observational

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
Interventions
Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Cerritos, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

NCT00041119
View directory record Official record
Conditions
Breast Cancer
Interventions
AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
3,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
526
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 359 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Interventions
LP-184, Olaparib, Nivolumab & Ipilimumab
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

NCT03929783
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Contrast Enhanced Digital Mammography
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

NCT02331251
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions
Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

NCT00617539
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

NCT00451022
View directory record Official record
Conditions
Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01207102
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abraxane, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00003877
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
3
States / cities
Detroit, Michigan • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

NCT00216073
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT05785741
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1310, Trastuzumab, Osimertinib, capecitabine
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

NCT04109066
View directory record Official record
Conditions
Breast Cancer
Interventions
nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery
Biological · Drug · Other + 1 more
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
30
States / cities
Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

NCT00404066
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 3, 2026, 10:13 AM EDT
Not listed Phase 2 Interventional

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

NCT01800422
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
telapristone acetate, placebo, therapeutic conventional surgery, laboratory biomarker analysis, questionnaire administration
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

NCT02312622
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
Interventions
Pegylated Irinotecan
Drug
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 3, 2026, 10:13 AM EDT
Completed No phase listed Observational Results available

Ibrance Real World Insights

NCT03159195
View directory record Official record
Conditions
Malignant Neoplasm of Breast
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

NCT02384239
View directory record Official record
Conditions
Metastatic Breast Cancer, Hormone Receptor Positive
Interventions
Palbociclib, Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 3, 2026, 10:13 AM EDT